The nitric oxide-cGMP signal transduction system acts as a """"""""brake"""""""" on cardiac function and metabolism and may be protective against excessive sympathetic tone in hypertrophy. In failure, the myocardial cGMP level is chronically elevated but its negative functional and metabolic effects are reduced due to a defect in its signaling pathway. The objective of this proposal is to determine the mechanism responsible for the maladaptation of the nitric oxide-cGMP system in heart failure and correct it. The hypothesis to be tested is that high cGMP levels in failure result in down-regulation of the cGMP dependent protein kinase and decreased phosphorylation of sarcoplasmic reticulum calcium ATPase and release channel.
The specific aim i s to determine and correct the defect of this signaling system by chronically lowering cGMP in failure and raising it in controls. Cardiac myocytes isolated from adult dogs with normal, hypertrophied (aortic stenosis) and failing (rapid pacing) hearts, as well as from transgenic mice (high/low basal cGMP) with and without aortic banding will be used to determine the defect in cGMP signaling and its effect on function (video-edge detection), calcium transients and O2 consumption. To assess the relative importance of these altered signaling processes, we will examine their effects on local work and O2 consumption in the intact heart. The in vivo studies will be conducted in anesthetized, open-chest dogs 6 months after induction of hypertrophy with or without failure and compared to controls. Regional myocardial work will be assessed from segment length (ultrasonic dimension crystals) and contractile force (miniature force gauges). O2 consumption of the same area will be determined from regional blood flow and regional O2 saturation of hemoglobin (microspectrophotometry). These physiological measurements will be combined with biochemical assays for cAMP and cGMP and the respective components of their signaling pathway. The ultimate goal is to determine if the cGMP signaling defect observed in failure is what initiates decompensation. Impact of the proposal: the understanding of the defect in the nitric oxide-cGMP signal transduction system will permit the development of novel treatment strategies for the secondary prevention of congestive heart failure in man.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL040320-12
Application #
6545838
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
Liang, Isabella Y
Project Start
1988-07-01
Project End
2006-06-30
Budget Start
2002-07-20
Budget End
2003-06-30
Support Year
12
Fiscal Year
2002
Total Cost
$507,480
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Surgery
Type
Schools of Medicine
DUNS #
622146454
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Tan, Tao; Scholz, Peter M; Weiss, Harvey R (2010) Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. Life Sci 87:9-16
Zhang, Qihang; Davidov, Tomer; Weiss, Harvey R et al. (2009) SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes. Pharmacology 83:223-30
Tan, Tao; Luciano, Jason A; Scholz, Peter M et al. (2009) Hypoxia inducible factor-1 improves the actions of positive inotropic agents in stunned cardiac myocytes. Clin Exp Pharmacol Physiol 36:904-11
Tan, Tao; Zhang, Qihang; Anyadike, Chukwuma et al. (2007) Chronic nitrates blunt the effects of not only nitric oxide but also natriuretic peptides in cardiac myocytes. Pharmacol Res 56:49-55
Feinberg, M S; Gussak, H M; Davila-Roman, V G et al. (1996) Dissociation between wall thickening of normal myocardium and cyclic variation of backscatter during inotropic stimulation. Am J Cardiol 77:515-20
Perez, J E; Davila-Roman, V G; Miller, J G (1995) Assessment of myocardial viability by ultrasonic tissue characterization. Coron Artery Dis 6:613-8